Cogent Biosciences, Inc.COGTNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank54
3Y CAGR-29.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-29.9%/yr
Quarterly compound
Percentile
P54
Within normal range
vs 3Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 7.82% |
| Q3 2025 | 13.01% |
| Q2 2025 | -3.15% |
| Q1 2025 | 1.59% |
| Q4 2024 | -2.47% |
| Q3 2024 | 17.17% |
| Q2 2024 | 3.01% |
| Q1 2024 | 8.18% |
| Q4 2023 | -2.81% |
| Q3 2023 | 28.96% |
| Q2 2023 | 7.86% |
| Q1 2023 | -1.92% |
| Q4 2022 | 22.74% |
| Q3 2022 | 1.55% |
| Q2 2022 | 15.74% |
| Q1 2022 | 24.16% |
| Q4 2021 | 38.63% |
| Q3 2021 | 19.45% |
| Q2 2021 | 50.83% |
| Q1 2021 | 34.46% |
| Q4 2020 | -88.23% |
| Q3 2020 | 912.15% |
| Q2 2020 | -46.00% |
| Q1 2020 | -8.27% |
| Q4 2019 | 0.18% |
| Q3 2019 | -2.66% |
| Q2 2019 | -14.40% |
| Q1 2019 | 15.22% |
| Q4 2018 | 5.00% |
| Q3 2018 | 12.34% |
| Q2 2018 | 12.09% |
| Q1 2018 | 7.67% |
| Q4 2017 | -7.52% |
| Q3 2017 | 14.51% |
| Q2 2017 | 2.72% |
| Q1 2017 | 0.00% |
| Q3 2016 | 0.00% |
| Q3 2015 | 0.00% |